LUPIN
|
|
BOM : 500257     NSE : LUPIN     | |
LT :  
    Long Term Analysis
Fundamentals : Average
Valuation : Average [Stock is fairly valued] Debt : Average |
Updated: |
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Upward
Price Momentum : Mild Upward Pledged Shares : None or < 25% |
Mar 18,2024 |
Price(EOD): ₹ 1,613.35
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
MCap: ₹ 73,504.23 Cr |
Industry Peers & Returns | 1W | 1M | 1Y |
LUPIN | -2% | -0.5% | 149.9% |
SUN PHARMACEUTICAL INDUSTRIES | -0.8% | 4% | 61.6% |
DIVIS LABORATORIES | -2.1% | -6% | 26.4% |
CIPLA | 1.5% | 3.3% | 70.6% |
DR REDDYS LABORATORIES | 0.7% | 0.4% | 44.6% |
TORRENT PHARMACEUTICALS | -4% | -2.8% | 70.3% |
ABBOTT INDIA | 6% | -3% | 39.7% |
ZYDUS LIFESCIENCES | 0.3% | 11.1% | 109.1% |
ALKEM LABORATORIES | -1.5% | -8.6% | 63.1% |
FUNDAMENTAL ANALYSIS OF LUPIN
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF LUPIN
 Ratio | Consolidated | |
---|---|---|
P/E P/B P/S |
40.62
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 1,809.74 Cr
[Latest Qtr - Dec2023 - Consolidated Results ] 5.97
P/B Calculated based on Book Value of Rs 12,315.60 Cr
[Latest Year - Mar2023 - Consolidated Results ] 3.77
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 19,480.10 Cr
[Latest Qtr - Dec2023 - Consolidated Results ] |
|
Financial Ratios → |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
12604% -4% -7% |
SHARE PRICE MOMENTUM OF LUPIN
LUPIN vs SENSEX
DEBT OF LUPIN
Year | Debt/Equity ratio | |
---|---|---|
Standalone | Consolidated | |
2023 2022 2021 Avg_3yrs |
0.03 0.04 0.02 0.03 |
0.34 0.32 0.35 0.34 |
[Last Annual Data : Mar2023]
|
||
Financial Ratios → |
PLEDGED PROMOTER SHARES OF LUPIN
Pledged Promoter Shares |
0 % | |
---|---|---|
As on : Dec2023 | ||
If less than 25% | Good |
|
If between 25% and 50% | Neutral | |
If greater than 50% | Bad | |
Shareholding Pattern → |
QTRLY RESULTS OF LUPIN
Consolidated | Q-o-Q | Y-o-Y |
---|---|---|
Revenue Op Profit Profit Before Tax Profit After Tax |
3.15% 11.35% 16.9% 24.91% |
20.25% 98.04% 199.06% 292.45% |
QtrlyTrend |
8 | |
Latest Qtr: Dec2023 | ||
Quarterly Result Analysis → |
LUPIN related INDICES
BSE Indices | 1W | 1M | 1Y |
---|---|---|---|
S&P BSE 100 ESG INDEX | -1.4% | 0% | 25.6% |
S&P BSE CARBONEX | -1.5% | 0.3% | 31.2% |
S&P BSE 100 | -1.6% | 0.2% | 31.5% |
S&P BSE LARGE MIDCAP | -1.9% | -0.1% | 35.5% |
S&P BSE 200 | -1.9% | -0.1% | 35.3% |
NSE Indices | 1W | 1M | 1Y |
---|---|---|---|
NIFTY GROWTH SECTOR 15 | 1.2% | 11.6% | 9.1% |
NIFTY PHARMA | -2% | 1.3% | 62.2% |
NIFTY 200 | -2% | -0.3% | 35.5% |
NIFTY HEALTHCARE | -2.1% | -1% | 59.4% |
NIFTY 500 | -2.2% | -1% | 37.3% |
You may also like the below Video Courses
FAQ about LUPIN
Is LUPIN good for long term investment?
As on Mar 18,2024, the Fundamentals of LUPIN look Average and hence you may wait for the results to improve to invest for long term ! See Financial Performance of LUPIN . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is LUPIN UnderValued or OverValued?
As on Mar 18,2024, LUPIN is Fairly Valued based on the estimates of intrinsic value and investors may wait for the buying opportunity once it becomes under valued!What is the Intrinsic Value of LUPIN ?
As on Mar 18,2024, the Intrinsic Value of LUPIN is Rs. 1,677.22 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 12.70
Fair Value [Median EV / Sales Model] : Rs. 1,677.22
Fair Value [Median Price / Sales Model] : Rs. 1,737.93
Estimated Median Fair Value of LUPIN : Rs. 1,677.22
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.